San Diego-based TRACON Pharmaceuticals, a firm developing cancer therapeutics, said this morning that it has raised $14M in a first tranche closing of a venture round. The round was led by JAFCO and Nextech Invest, and also included Arcus Ventures, BHP, and Brookline Investments. JAFCO's Kenji Harada and Hironori Hozoji, and Nextech Invest's Myoung-Ok Kwon have all joined the company's board along with the funding. TRACON is developing antibodies for treating prostate, bladder, and liver cancer. More information »